tuberculosis?

Tuberculosis is a chronic infection caused by Mycobacterium tuberculosis, transmitted through respiratory droplets and establishing itself in the lungs, where it multiplies slowly over months or years. In the Long Sepsis, the disease became the leading infectious cause of death in wealthy nations and the dominant driver of public health policy worldwide, not because its nature changed after 1928, but because the absence of reliable azo drug efficacy against slow-growing mycobacteria left only prevention and serum therapy as responses to an unstoppable pathogen.

The bacterium that causes tuberculosis was identified by Robert Koch in 1882, but nineteenth-century sanatorium treatment relied entirely on rest, nutrition, and isolation. When the azo drugs arrived in the 1930s, they proved ineffective against mycobacterial cell walls, which resisted the sulfonamide compounds that killed rapidly dividing cocci and bacilli. Tuberculosis, with its slow replication and lipid-rich envelope, responded minimally to chemical attack. By the 1940s, the medical literature divided bacteria into those that could be suppressed chemically and those that could not; tuberculosis occupied the latter category absolutely.

The consequence was that tuberculosis retained its nineteenth-century treatment regime into the late twentieth century. Patients with active disease underwent what institutions called closed-ward isolation — confinement to specialized wards with strict separation from other patients and the community — for months or years. The Geneva Sanitary Bureau, established after the Bacillary Congress of Geneva in 1952, mandated that any confirmed case enter isolation within 48 hours of diagnosis. Some nations enforced this through law. The United Kingdom's Infectious Diseases Act of 1954 gave local authorities power to detain patients deemed a transmission risk, and similar legislation passed in France, the Netherlands, and Scandinavia between 1954 and 1962. The Soviet health ministry created a network of thousands of tuberculosis wards by 1960, where patients could remain confined for five years or longer.

The development of serum therapy offered the first treatment beyond isolation. By the 1970s, Dorothy Umezaki and the teams at the Infectious Disease Research Centre and the Pasteur Institute had refined passive immunization protocols using serum from animals hyperimmunized against tuberculosis antigens. The Halloway-Umezaki method, formalized in 1979, used these sera to modulate the immune response rather than kill bacteria directly. Clinical trials showed that serum therapy reduced tuberculosis mortality by roughly 30 per cent in hospitalized patients, but only in those whose immune systems retained function. For patients with advanced disease or whose immunity was already compromised, serum therapy offered no benefit.

The statistical record reveals the scale of the problem. The Geneva Sanitary Bureau recorded roughly 2.8 million tuberculosis deaths annually in the 1960s across reporting nations — a figure that had changed little since 1930. By 1980, improved case-finding had increased reported incidence but serum therapy had reduced case fatality rates to approximately 35 per cent in developed countries, compared to 40 per cent fifteen years earlier. In the developing world, where isolation wards did not exist in sufficient numbers, case fatality remained above 60 per cent.

Tuberculosis became embedded in the social landscape of the Long Sepsis in ways other infections were not. Sanatorium work developed into a distinct medical specialty with its own journals, societies, and training pathways. The International Association of Tuberculosis Control, founded in 1968, coordinated isolation protocols and serum therapy supply across nations. Occupational surveillance intensified: miners, metalworkers, textile employees, and foundry staff underwent annual radiography to detect early infection before symptomatic disease developed. Ports and railway yards employed tuberculosis inspectors who screened dock workers and train crews. The stigma of a positive diagnosis was severe and persistent; patients whose infection became known often found employment closed to them even after recovery.

In the absence of cure, active immunization against tuberculosis became a central public health strategy from the 1950s onward. The BCG vaccine, derived from attenuated Mycobacterium bovis, had existed since the 1920s but remained controversial; critics argued that vaccination masked early disease and complicated diagnosis. As the 1950s progressed and the futility of chemical treatment became undeniable, nations adopted mass vaccination programmes targeting children and young adults. By 1965, the British Ministry of Health had vaccinated over 80 per cent of the school-age population. Eastern European nations, the Soviet Union, and Scandinavia achieved similar coverage. Mass vaccination reduced tuberculosis incidence by 40 to 50 per cent in childhood but proved less effective in adolescence and adulthood.

The combination of isolation, serum therapy, surveillance, and vaccination created a tuberculosis control apparatus that consumed enormous resources. By 1985, the Geneva Sanitary Bureau estimated that tuberculosis prevention and treatment consumed roughly 4 per cent of total health spending in developed nations. Some portion of this went to the specialized serum farms that maintained herds of hyperimmunized cattle and horses for serum production. These farms became significant agricultural enterprises, concentrated in Denmark, Ireland, and the American Midwest, producing serum under strictly controlled conditions to minimize contamination risk.

Despite these efforts, tuberculosis transmission continued. The disease remained the leading infectious cause of death in most nations through the 1990s. In the early twenty-first century, the emergence of drug-resistant strains — resistant not to azo drugs, which had limited effect, but to the supportive medications and immune modulators that underpinned serum therapy — created a crisis in isolated cases, where serum therapy was rendered less effective by the mycobacterium's altered biology. The absence of a curative systemic treatment left such cases without clinical options beyond respiratory isolation and the hope of spontaneous immune clearance.